Superior Bioavailability of EPA and DHA from a L-lysine Salt Formulation: a Randomized, Three-way Crossover Study

Overview

Journal Food Nutr Res

Date 2025 Jan 9

PMID 39781273

Authors

Christiane Schon

Antje Micka

Vishnupriya Gourineni

Roberta Bosi

Affiliations

Soon will be listed here.

Abstract

Background: Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are polyunsaturated fatty acids (PUFAs) with notable health benefits. Due to limited physiological production and insufficient dietary supply, external supplementation is important.

Objective: This study aimed to compare the pharmacokinetics and bioavailability of EPA and DHA in AvailOm omega-3-lysine salt (Lys-FFA) versus standard ethyl ester (EE) and triglyceride (TG) formulations after a single oral dose in healthy subjects.

Design: A randomized, three-way crossover study was conducted with 21 healthy subjects.

Results: Twenty-one subjects (10 men, 11 women) completed the study. The average age was 41.7 years, and the mean body mass index was 23.0 kg/m. The Lys-FFA formulation showed significantly higher uptake of omega-3 fatty acids (EPA+DHA combined and each individually) compared to EE. Specifically, Lys-FFA had a 9.33-fold (0-12 h) and 8.09-fold (0-24 h) higher bioavailability of EPA+DHA than EE and a 1.57-fold (0-12 h) and 1.44-fold (0-24 h) higher bioavailability than TG. ΔCmax and Tmax also favored Lys-FFA over EE.

Discussion: Under fasting conditions, the absorption of EPA and DHA from EE is limited due to the need for enzymatic cleavage before absorption. This requirement is bypassed with Lys-FFA, which does not need cleavage.

Conclusions: The study demonstrates that EPA and DHA lysine salt (Lys-FFA) offers superior bioavailability compared to EE and triglyceride forms, presenting a more effective supplementation option.German Clinical Trials Register, DRKS-ID: DRKS00029183.

References

Dicklin M, Anthony J, Winters B, Maki K . ω-3 Polyunsaturated Fatty Acid Status Testing in Humans: A Narrative Review of Commercially Available Options. J Nutr. 2024; 154(5):1487-1504. DOI: 10.1016/j.tjnut.2024.03.015. View

Schuchardt J, Hahn A . Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013; 89(1):1-8. DOI: 10.1016/j.plefa.2013.03.010. View

Cholewski M, Tomczykowa M, Tomczyk M . A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids. Nutrients. 2018; 10(11). PMC: 6267444. DOI: 10.3390/nu10111662. View

Manusama K, Balvers M, Diepeveen-de Bruin M, Headley L, Bosi R, Schwarm M . In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA. Prostaglandins Leukot Essent Fatty Acids. 2020; 164:102232. DOI: 10.1016/j.plefa.2020.102232. View

Abedi E, Sahari M . Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr. 2014; 2(5):443-63. PMC: 4237475. DOI: 10.1002/fsn3.121. View

Offman E, Marenco T, Ferber S, Johnson J, Kling D, Curcio D . Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag. 2013; 9:563-73. PMC: 3794864. DOI: 10.2147/VHRM.S50464. View

Innes J, Calder P . Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020. Int J Mol Sci. 2020; 21(4). PMC: 7072971. DOI: 10.3390/ijms21041362. View

Lane K, Derbyshire E, Li W, Brennan C . Bioavailability and potential uses of vegetarian sources of omega-3 fatty acids: a review of the literature. Crit Rev Food Sci Nutr. 2013; 54(5):572-9. DOI: 10.1080/10408398.2011.596292. View

Fuentes N, Kim E, Fan Y, Chapkin R . Omega-3 fatty acids, membrane remodeling and cancer prevention. Mol Aspects Med. 2018; 64:79-91. PMC: 6185832. DOI: 10.1016/j.mam.2018.04.001. View

10.

Lowe M . The triglyceride lipases of the pancreas. J Lipid Res. 2002; 43(12):2007-16. DOI: 10.1194/jlr.r200012-jlr200. View

11.

Maki K, Palacios O, Buggia M, Trivedi R, Dicklin M, Maki C . Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State. Clin Ther. 2018; 40(12):2065-2076. DOI: 10.1016/j.clinthera.2018.10.014. View

12.

Swanson D, Block R, Mousa S . Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr. 2012; 3(1):1-7. PMC: 3262608. DOI: 10.3945/an.111.000893. View

13.

Calder P . Very long-chain n-3 fatty acids and human health: fact, fiction and the future. Proc Nutr Soc. 2017; 77(1):52-72. DOI: 10.1017/S0029665117003950. View

14.

Givens D, Gibbs R . Current intakes of EPA and DHA in European populations and the potential of animal-derived foods to increase them. Proc Nutr Soc. 2008; 67(3):273-80. DOI: 10.1017/S0029665108007167. View

15.

Lohner S, Fekete K, Marosvolgyi T, Decsi T . Gender differences in the long-chain polyunsaturated fatty acid status: systematic review of 51 publications. Ann Nutr Metab. 2013; 62(2):98-112. DOI: 10.1159/000345599. View